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QT/QTc Study in Healthy Volunteers
Jeike Biewenga1, Chi Keung2, Bhavna Solanki2, Jaya Natarajan2, Gerhard Leitz2,
Sofie Deleu1, and Paul Soons1
Abstract
Domperidone effects on QTc duration were assessed in a single‐center, double‐blind, four‐way crossover study of
44 healthy participants randomized to one of four treatment sequences consisting of four treatment periods
separated by 4–9 days washout. On Day 1 of each 4‐day period, participants began oral domperidone 10 or 20mg q.i.
d., matching placebo q.i.d., or single‐dose moxifloxacin 400mg (positive control)/placebo q.i.d. In each period,
triplicate 12‐lead electrocardiograms were recorded at baseline (30, 20, and 10minutes predose), 8 timepoints after
dosing on Days 1 and 4, and predose on Day 4. In mixed effects models, the largest difference for domperidone in
least squares means for change from baseline QTcP versus placebo was 3.4milliseconds (20mg q.i.d., Day 4), 90% CI:
1.0–5.9, and <10milliseconds at all timepoints for both domperidone dosages. Moxifloxacin response confirmed
assay sensitivity. Participants achieved expected domperidone plasma exposures. No significant exposure‐response
relationship was found for QTc increase per ng/mL domperidone (90% CI of the slope estimate included zero at
mean Cmax on Day 1 or Day 4). In summary, domperidone at doses up to 80mg/day did not cause clinically relevant
QTc interval prolongation.
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Domperidone, a peripheral dopamine receptor antagonist
with gastrokinetic and anti-emetic properties,1 has been
marketed for over 35 years in more than 100 countries for
the relief of nausea and vomiting symptoms, epigastric
sense of fullness, upper abdominal discomfort, and
regurgitation of gastric contents in adults, and for the
relief of nausea and vomiting symptoms in children. The
highest dose approved globally for prescription use in
adults is 20mg up to four times daily (q.i.d.), that is, up to
80mg/day.2
Non-clinical data, clinical studies, and post-marketing
safety case reports have suggested that domperidone at
very high concentrations (e.g., following high doses
administered intravenously [IV] via bolus injection or
rapid infusion) has a propensity to prolong theQT interval
and result in cardiac conduction adverse events.3
Nonetheless, a large cardiovascular safety margin of
domperidone was confirmed in a comprehensive range of
non-clinical studies and an “Integrated Risk Assessment”
per the International Conference on Harmonisation (ICH)
S7B guidelines.4
Clinical study and extensive post-marketing experi-
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sudden death are very rare events after oral administration
of domperidone. Some epidemiology studies have shown
a significant association between domperidone and
serious ventricular arrhythmia (SVA)/sudden cardiac
death (SCD); however, these studies do not address the
question of whether this association is causal or due to
potential confounders such as smoking, obesity, or
alcohol use, which are not well captured in the health
services databases used to conduct these studies. In
addition, only one study5 offered information on the
relationship of age to the risk of SCD, and only one study6
offered information on the relationship of domperidone
dose to the risk of SCD.
The PharmacovigilanceWorking Party (PVWP) of the
European Medicines Agency (EMA) evaluated available
preclinical and clinical data related to the cardiac safety of
domperidone and concluded in October 2011 that the
benefit-risk remained positive.7 To further inform this
position, European agencies requested that an ICH-E14
QT/QT corrected for heart rate (QTc) study8 be
conducted for labeled doses of domperidone. We report
herein the results of this thorough QT/QTc study of
domperidone, which advances our understanding of the
cardiac safety of domperidone.
The primary objective of the study was to assess the
effects of single and multiple doses of domperidone on
QTc duration in healthy adult volunteers at domperidone
doses of 10 and 20mg q.i.d. Secondary objectives of the
study were to: assess the relationship between the dose of
domperidone and QTc changes for single and multiple
doses; evaluate the single- and multi-dose pharmacoki-
netics (PK) of domperidone; assess the relationship
between plasma concentrations of domperidone and
QTc changes, both for single and multiple doses of
domperidone; and, evaluate the safety and tolerability of
domperidone, including effects on electrocardiogram




Eligibility criteria required that study participants were
healthy, non-smoking male and female volunteers aged
18–55 years old, with body mass index (BMI) of 18–
30 kg/m2, body weight 50 kg, systolic blood pressure
90–140mmHg, diastolic blood pressure 90mmHg,
and heart rate 45–100 beats per minute (bpm)/normal
sinus rhythm. With regard to ECG at screening and
baseline, participants were required to have a QT
interval corrected for heart rate using Fridericia
formula (QTcF) of 350–450milliseconds, QRS interval
of <110milliseconds, PR interval <200milliseconds,
and morphology consistent with healthy cardiac con-
duction and function.
Eligibility criteria also required that participants did
not have a current, clinically significant medical illness,
including cardiac arrhythmias or other cardiac disease, at
the time of study screening, family history of Short QT
Syndrome or Long QT Syndrome, and hypo- or hyper-
kalemia, -magnesemia, or -calcemia. In addition, they
were not to be treated with any prescription or over-the-
counter medications within 14 days of Day 1 of the first
treatment period, with the exception of paracetamol,
continued use of a hormonal intrauterine device and, if
female, was not pregnant or lactating.
Study Design
This randomized, double-blind, four-way crossover,
placebo- and positive-controlled, single- and multiple-
dose phase 1 study was conducted between 31 July and
05 November 2012 at a single study center in Belgium.
The design followed the general design principles
outlined in the ICH-E14 guidance for the clinical
evaluation of the QT/QTc interval with non-antiarrhythmic
drugs.8
The study consisted of three phases: a screening phase,
a double-blind treatment phase, and a post-treatment
phase. Volunteers were screened for eligibility between
Day21 and Day2. The treatment phase included four
treatment periods each consisting of a baseline assess-
ment and stabilization day (Day 1) and a 4-day
treatment period (Day 1–Day 4), with each treatment
period separated by a 4- to 9-day washout. End-of-study
procedures were conducted 4–10 days after the last dose
of study drug in the final treatment period or at the time of
early withdrawal.
At the beginning of the double-blind treatment
phase, eligible volunteers (criteria summarized above)
were assigned to one of four treatment sequences based
on a computer-generated randomization schedule.
Randomization was balanced using randomly permuted
blocks. On Day 1 of each treatment period, participants
began domperidone 10 or 20mg q.i.d. (dosing at 0,
5 hours and 10minutes, 10 hours, and 15 hours), match-
ing placebo q.i.d., or single-dose moxifloxacin 400mg
(positive control)/placebo q.i.d., taking the remaining
study drugs in order based on the treatment sequence.
Study drugs were over-encapsulated to maintain the
double-blind.
An independent Ethics Committee (Comité voor
Medische Ethiek, University Hospital Antwerp, Ede-
ghem, Antwerp, Belgium) reviewed and approved the
study protocol. The study was conducted in accordance
with the ethical principles that have their origin in the
Declaration of Helsinki, consistent with Good Clinical
Practices and applicable regulatory requirements. All
participants provided written informed consent before
their study participation commenced. The study is
registered at www.clinicaltrials.gov, NCT 01643889.
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Assessments
ECG/QTc. In each treatment period, serial 12-lead
ECGs were recorded in triplicate during the first dosing
interval at 30, 20, and 10minutes before dosing on Day 1
(the average of which was defined as baseline), at
10minutes before dosing (predose) on Day 4, and at 8
(0.5, 1, 1.5, 2, 2.5, 3, 4, 5 hours) post-dose timepoints on
Days 1 and 4, always before PK sampling. During the
collection of ECGs, participants were in a quiet setting
without distractions, rested in a supine position for at least
10minutes before ECG collection, and refrained from
talking or moving arms or legs. To minimize the effect of
food on ECG assessments, participants’ meal intake and
content during residence at the study center were strictly
controlled, with them having limited access to only water
from 2 hours before to 3 hours after the morning drug
administration and fluids other than water, but no food,
between 3 and 5.5 hours after dosing on Day 1 and Day 4.
In addition, for safety monitoring, ECGwasmonitored by
telemetry from 6 hours after the morning dose on Day 1
until 2 hours before dosing on Day 4 in each treatment
period.
A blinded reader at a central laboratory (Quintiles
Limited, Cardiac Safety Services, Mumbai, India)
measured ECG interval durations using a high-resolu-
tion, semi-automatic (computer-assisted) on-screen
annotation (caliper) method. A blinded cardiologist at
the central laboratory evaluated all triplicate ECGs for
abnormalities (rhythm, axis, conduction, hypertrophy,
myocardial infarction, and ST-, T-, and U-wave
morphology), with focus on T- and U-wave morpholo-
gy, according to predefined criteria. The reader and
cardiologist at the central laboratory were blinded to
treatment (domperidone vs. placebo vs. moxifloxacin),
treatment period, dosing day within period (baseline vs.
on-drug), timepoint within the day, and the participant
identifiers.
Clinically significant findings on ECGs observed by
the investigator were reported as adverse events, whereas
those observed post-hoc by the cardiologist at the central
laboratory were included in the statistical analysis but not
reported as adverse events.
Pharmacokinetics. Venous blood samples of 4mLwere
taken at 10minutes before dosing and at 8 predefined
timepoints after dosing (within 5minutes after the last of
the triplicate 12-lead ECG recording) on Day 1 and Day 4
of each period for the determination of plasma concen-
trations of domperidone. The whole blood samples for PK
evaluation were centrifuged at room temperature for
10minutes, beginning within 2 hours of collection; the
resulting 1.7mL plasma samples were frozen within
2 hours of whole blood sample collection and stored at
approximately 20˚C until transferred to the bioanaly-
tical facility (PRA Early Development Services, Assen,
The Netherlands) for analysis.
Concentrations of domperidone in EDTA plasma were
determined using a validated,9,10 sensitive liquid chro-
matography–tandem mass spectrometry (LC–MS/MS)
method. The method consisted of a solid-phase extraction
in a micro-elution plate with Oasis MCX, followed by
reversed phase chromatography using a Waters XBridge
C18 column (Waters, Milford, MA) using a HTC PAL
autosampler (CTC Analytics, Zwingen, Switzerland)
with LC-10Advp pump (Shimadzu, Columbia, MD)
coupled with a Applied Biosystems/MDS SCIEX
API3000 triple quadrupole mass spectrometer. The
quantification range was 1–500 ng/mL.
PK parameters were calculated for domperidone using
standard non-compartmental analysis methods.
Non‐ECG Safety Assessments. Adverse events were
monitored, clinical laboratory tests were performed,
physical examinations were conducted, and vital signs
were measured at prespecified timepoints throughout the
conduct of this study.
Data Analysis
Sample Size Determination. Based on a SD of 10milli-
seconds for change from baseline in QTc (DQTc) as
observed in previously conducted thorough QT studies
using a crossover design, a sample size of 36 subjects
would be sufficient for the estimate of the difference in
change from baseline QTc between each treatment and
placebo (DDQTc; point estimate) to be within 4milli-
seconds of its true value with 90% confidence at each
timepoint of measurement.
Assay sensitivity was assessed by evaluating the
difference in mean DDQTc between moxifloxacin and
placebo when averaged over the four timepoints between
2 and 4 hours after dosing.11 With an intrasubject SD of
10milliseconds and a sample size of 36 subjects, the
probability that the lower limit of the two-sided 90%
confidence interval (CI) exceeded 5milliseconds was
estimated to be 80% when the true difference in means
was 11milliseconds.
Pharmacodynamic (ECG/QTc) Analyses. Heart rate, QT
interval, and change from baseline in heart rate and QT
for each treatment and timepoint of measurement were
summarized using descriptive statistics, as was the
difference in the change from baseline in heart rate and
QT between each domperidone dose and placebo.
The primary correction method for QT intervals
was selected based on an evaluation of baseline (QTc,
RR) data for three correction methods (Fredericia
[QTcF], Bazett [QTcB], study-specific power [QTcP]).
Regression modeling of the logarithm of QTc versus
logarithm of RR was used for this evaluation to allow
objective selection of the method; the correction
method with the lowest value for the upper 95% CI
limit for estimated slope was selected as the primary
correction.
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Mixed effects models with sequence, treatment,
period, timepoint of measurement, and treatment-by-
timepoint interaction as fixed effects and participant as
a random effect was fit to DQTc data. Using the
estimated least squares (LS) means and intrasubject
variance from the model, 90% CIs for the difference in
means between each treatment and placebo (DDQTc)
and for the difference between the two doses of
domperidone were constructed at each timepoint of
measurement.
In concordance with the ICH-E14 guidance, a
threshold level of QTc change was defined as >5milli-
seconds, as evidenced by an upper limit of two-sided 90%
CI for the difference inmeans exceeding 10milliseconds.8
Pharmacokinetic Analyses. Domperidone plasma con-
centration data and its derived PK parameters were
summarized for a single dose (Day 1) and after multiple
dosing (Day 4) for both domperidone dosages (10 and
20mg) using descriptive statistics.
Pharmacokinetic/Pharmacodynamic Analyses The DDQTcP
between each dose of domperidone and placebo at each
timepoint of measurement was plotted against the corre-
sponding plasma concentration of domperidone.
Linear mixed effects models were fit to the DDQTcP
data for treatment Day 1 and Day 4, separately, with
concentration as a predictor and subject as a random
effect; if the intercept term was not significant, the model
was re-fitted with a zero intercept term. The model-
estimated value of DDQTcP and two-sided 90% CIs were
calculated at the mean observed maximum plasma
concentration (Cmax) values at Day 1 and Day 4 for
each domperidone dose.
Results
The study population was comprised of 44 volunteers,
with the majority being white (n¼ 42, 95%) and male
(n¼ 32, 73%). The mean (SD) age was 43.5 (8.0) years
and BMI, 24.7 (2.8) kg/m2.
Of the 44 volunteers enrolled, 40 completed the
study and 4 discontinued prematurely: 1 due to an
adverse event (allergic dermatitis during moxifloxacin
treatment in period 3 after completing domperidone
placebo and domperidone 20mg), 1 due to a protocol
violation (confirmed positive drug screen after domper-
idone placebo in treatment period 1), 1 due to family
reasons (after 2 days of moxifloxacin in treatment period
1), and 1 due to conflicting work schedule and was not
available for period 3 and period 4 (after completing
domperidone 20mg in period 1 and domperidone 10mg
in period 2).
All 44 participants were included in QTc and safety
analyses, 42 had at least 1 post-dose PK concentration
measurement and were included in PK analyses, and 41 of
42 were included in PK/PD analyses.
Pharmacodynamics
On Day 1, mean heart rate values for domperidone
10mg, domperidone 20mg, moxifloxacin 400mg, and
placebo ranged, respectively, from 57.8 to 62.4, 57.3 to
62.4, 57.7 to 62.4, and 57.4 to 63.2 bpm. On Day 4, mean
heart rate values for the respective treatment groups
ranged from 60.1 to 64.7, 57.8 to 64.5, 59.4 to 64.4, and
59.3 to 64.4 bpm. For both doses of domperidone, the
difference in mean change from baseline in heart rate
between domperidone and placebo ranged from 1.3 to
2.1 bpm. The 95% CI for the difference in mean change
from baseline in heart rate between domperidone and
placebo included 0 bpm at all except two timepoints (1
and 2 hours post-dose on Day 1 for domperidone 20mg
vs. placebo).
On Day 1, mean QT interval values for domperidone
10mg, domperidone 20mg, moxifloxacin, and placebo
ranged from 401.9 to 415.1, 401.2 to 413.9, 402.2 to
425.1, and 400.5 to 414.0milliseconds, respectively. On
Day 4, mean QT interval values for the respective
treatment groups ranged from 393.5 to 406.2, 393.2 to
410.4, 393.6 to 407.0, and 392.3 to 407.6milliseconds.
For both doses of domperidone, the difference in mean
change from baseline in QT intervals between domper-
idone and placebo ranged from 3.6 to 3.6milliseconds.
The 95% CI for the difference in mean change from
baseline in QT intervals between domperidone and
placebo included 0millisecond on both days and at all
timepoints.
QTcP was selected as the primary correction method
(correction factor¼ 0.2434). Results for QTcF and
QTcB were consistent with that of QTcP. The difference
in LS means for change from baseline QTcP for the
positive control, moxifloxacin, versus placebo, averaged
over timepoints between 2 and 4 hours, was 10.3milli-
seconds (90% CI: 9.4–11.2), and the moxifloxacin
response confirmed assay sensitivity (Figure 1). For
domperidone, the largest difference in LS means for
change from baseline QTcP for domperidone versus
placebo was 3.4milliseconds (90% CI: 1.0–5.9), which
occurred at 1 hour post-dose on Day 4 during 20mg q.i.
d. dosing (Table 1 and Figure 1). When a typically
used domperidone dose of 10mg q.i.d. was given, the
largest difference in LS means for change from baseline
QTcP for domperidone versus placebo was 2.0milli-
seconds (90% CI: 0.2–3.8). The upper limit of the
90% CI was <10milliseconds at all timepoints on Day 1
(after single dose) and Day 4 (after multiple doses) for
both domperidone doses. The largest difference in LS
means for change from baseline QTcP between the 20
and 10mg doses of domperidone was 1.2milliseconds
(90% CI: 0.6 to 3.0) at Day 1 and 2.7milliseconds
(90% CI: 0.3 to 5.1) at Day 4. Results for QTcF and
QTcB (data not shown) were consistent with that of
QTcP.
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Pharmacokinetics
Participants achieved expected domperidone exposures
(Cmax and area under the plasma concentration–time
curve [AUC]) (Table 2). PK parameters were close to
proportional for domperidone 10 and 20mg doses; an
approximately two- to three-fold accumulation was found
on Day 4 of domperidone treatment. The between-subject
variability (% coefficient of variation) for Cmax and AUC
was less than 51% following a single dose and less than
40% following multiple doses.
Pharmacokinetics/Pharmacodynamics
No significant or clinically relevant exposure-QTc
response effects were observed at Day 1 or Day 4 of





























Domperidone 10 mg q.i.d.
Domperidone 20 mg q.i.d.
Figure 1. Difference between each treatment and placebo based on mixed effects modeling on QTcP changes from baseline (LS
mean and 90% CI).
Table 1. Maximum Difference in LS Mean QTcP—Active Drug versus Placebo
Comparison Visit
Maximum differences in LS means
at any timepoint (QTcP) 90% CI
Domperidone 10mg vs. placebo Day 1 2.0 (0.2, 3.8)
Domperidone 10mg vs. placebo Day 4 1.1 (1.3, 3.6)
Domperidone 20mg vs. placebo Day 1 1.7 (0.1, 3.5)
Domperidone 20mg vs. placebo Day 4 3.4 (1.0, 5.9)
Moxifloxacin vs. placebo Day 1 10.3a (9.4, 11.2)
CI, confidence interval; QTcP, QT interval corrected for heart rate, using a study‐specific power model.
aAveraged over all timepoints between 2 and 4 hours after dosing.
Table 2. Summary of Pharmacokinetic Parameters
Mean (% CV)
Domperidone 10mg Domperidone 20mg
Day 1 (N¼ 40) Day 4 (N¼ 40) Day 1 (N¼ 41) Day 4 (N¼ 41)
Cmin (ng/mL) NA 5.26 (31.1%) NA 10.1 (29.7%)
Cmax (ng/mL) 11.6 (50.8%) 17.3 (35.4%) 20.1 (48.2%) 35.7 (39.9%)
tmax (h)
a 1.02 (0.52–5.02) 1.02 (0.5–4.03) 1.03 (0.52–4.03) 1.02 (0.50–2.52)
AUC0–5 h (ng · h/mL) 20.4 (34.4%) 47.8 (30.5%) 38.2 (38.0%) 96.4 (28.9%)
AUC0–5 h, area under the plasma concentration–time curve over the first dosing interval (from 0 to 5 hours); Cmin, minimum plasma concentration;
Cmax, maximum plasma concentration; CV, coefficient of variance; q.i.d., four times daily; NA, not applicable; tmax, median time to reach Cmax.
aMedian (range).
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domperidone treatment (Figure 2). On Day 1, the model-
estimated increase in DDQTcP at the mean Cmax was
0.029milliseconds for the 10mg dose and 0.0503milli-
seconds for the 20mg dose, and on Day 4 the estimated
increase was 1.07milliseconds for the 10mg dose and
2.21milliseconds for the 20mg dose, with the 90% CI
including zero at mean Cmax for both days. As a result of
distance in time from the baseline QTc measurement, the
variability in DDQTcP on Day 4 was larger than that on
Day 1, resulting in a wider CI for the slope.
ECG Intervals and Morphology
No participant had a QTcP interval >450milliseconds
during treatment with domperidone 20mg, moxifloxacin,
or placebo. One participant (baseline value 443.1milli-
seconds) had two QTcP intervals >450milliseconds
measured during domperidone 10mg treatment—456.1
at 3 hours post-dose on Day 1 and 452.5milliseconds at
5 hours post-dose on Day 4. No participant had a
>30milliseconds change from baseline in QTcP interval
during treatment with domperidone 10mg, domperidone
20mg, or placebo. After a moxifloxacin dose, one
participant had a >30milliseconds increase from
baseline QTcP value at 5 hours post-dose on Day 1
(412.6–443.5milliseconds).
ECG morphology abnormalities occurred infrequent-
ly, were balanced in frequency across the treatment
groups, and were all determined to be clinically
insignificant in blinded review. Non-specific, flat T-
wave abnormalities were observed in one participant each
in the placebo and domperidone 20mg groups and two
participants each in the domperidone 10mg and moxi-
floxacin groups. There were no abnormalities in U-wave
morphology. There were no other treatment-emergent
ECG abnormalities or ECG morphology findings.
Other Safety Findings
The overall incidence of treatment-emergent adverse
events was numerically lower in the domperidone 10mg
group (19.5%; 8/41) than in the placebo group (33.3%;
14/42) and the domperidone 20mg and moxifloxacin
400mg groups (each 28.6%; 12/42). The most common
events (i.e., reported in 5% patients in any treatment
group) were skin irritation at the site of ECG electrodes
application, which was reported in 5 (11.9%) of 42
participants in the placebo treatment group, and headache
in 3 (7.1%) of 42 participants in moxifloxacin 400mg
treatment group. The investigator assessed all events as
either mild or moderate in severity. One participant
discontinued study drug prematurely due to an adverse
event of allergic dermatitis during treatment with
moxifloxacin. No clinically significant changes in
laboratory tests were observed during the study.
Discussion
In this current study, the results showed the largest
difference in LS means for change from baseline QTcP
for both domperidone 10 and 20mg q.i.d. doses versus
placebo was below 5milliseconds, and the upper limit of
the 90% CI was well below 10milliseconds at all
timepoints on Day 1 (after single dose) and on Day 4 (after
multiple doses), indicating that this is a negative thorough
QT/QTc study.8 There were no abnormalities in U-wave
morphology or other treatment-emergent ECG abnormali-
ties or ECG morphology findings associated with the








































Figure 2. Individual domperidone plasma concentration versus DD QTcP and estimated linear mixed effects model. Solid line
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administration of domperidone. Doses exceeding the
highest dose approved globally for prescription use of
domperidone were not tested in this study because
preclinical electrophysiological in vitro and in vivo studies
havealreadyshown thatdomperidone, at veryhighconcen-
trations, may prolong the QTc interval, without arrhyth-
mogenic or torsadogenic effects at these concentrations.2
Historically, in less well controlled studies, when
domperidone was given together with the strong CYP3A4
inhibitors ketoconazole or erythromycin, drugs that
prolong QT by themselves, the upper limit of the 90%
two-sided CI for the largest mean difference in change of
QTc from baseline versus placebo was shown to exceed
10milliseconds.2 Domperidone is metabolized by
CYP3A4 enzymes,12 and the Cmax of domperidone has
been shown to increase less than three-fold under
maximal CYP3A4 inhibition. In those interaction studies,
the mean increase in QTc for domperidone 10mg q.i.d. at
steady-state was 1.6–2.5milliseconds, and for ketocona-
zole (200mg b.i.d.) and erythromycin (500mg t.i.d.), 3.8
and 4.9milliseconds, respectively. For the combined
treatment of domperidone with ketoconazole or erythro-
mycin, the mean increase in QTc was 9.8–9.9milli-
seconds.2 Thus, domperidone is not recommended to be
administered concomitantly with strong CYP3A4 inhib-
itors that also prolong QT.
Several animal models have been used to investigate
the electrocardiographic effects of domperidone. In
anesthetized and conscious dogs, safety margins for QT
prolongation were greater than 25- and nine-fold plasma
concentrations at maximum recommended therapeutic
doses, respectively, and in a rabbit proarrhythmia model,
no proarrhythmia was observed at concentrations 367-
fold plasma concentrations at maximum recommended
therapeutic doses. In an isolated Langendorff-perfused
rabbit heart model (Hondeghem ScreenitTM system),
no effects were found on proarrhythmic parameters at
100 nM (17-fold margin). TdP was observed in one of six
hearts at 300 nM (52-fold margin) and in three of six
hearts at 1,000–3,000 nM (173- to 519-fold margin). A
subsequent publication of an extensive validation of this
isolated heart test system found comparable results and
margins for domperidone.13 However, publications of
more recent experiments using the ScreenitTM system,
revised to enhance sensitivity, have shown effects of
domperidone at lower concentrations by using a lower
concentration range (30, 60, and 100 nM), a higher
incubation temperature of 37˚C, and a longer exposure
time of 150minutes.14,15 These changes to the experi-
mental protocol, as well as the absence of concurrent
vehicle controls and the lack of blinded validation of the
revised model with a series of other drugs with and
without known arrhythmogenic liabilities in humans, as
was done previously,13 limit the relevance of the testing
model for predicting safety and informing the assessment
of risk in humans. Furthermore, the relevance of
nonclinical studies with domperidone is progressively
being outweighed by accruing post-marketing safety
information and clinical trial evidence as reported herein.
In summary, domperidone at doses up to 80mg/day—
the highest oral dose approved globally for prescription
use—did not cause clinically relevant prolongation of the
QTc interval in this thorough QT study. No new safety
signal was observed in this study based on assessments
of ECG morphology, adverse events, or changes in
laboratory parameters.
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